Human CAR T cells engineered with purified CD19 mRNA exerted a twofold increase in cytotoxicity towards the Nalm-6 cell line and a 100-fold inhibition of leukemia burden in humanized ALL mice with enhanced persistence. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.